JANSSEN PHARMACEUTICAL K.K.

🇯🇵Japan
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

A Study of the Safety, Tolerability, Pharmacokinetics (What the Body Does to the Drug), and Pharmacodynamics (What the Drug Does to the Body) of CNTO 1959 Following a Single Subcutaneous (Under the Skin) Administration in Japanese Participants With Moderate to Severe Plaque Psoriasis

Phase 1
Completed
Conditions
Psoriasis
Interventions
Drug: CNTO 1959
Drug: Placebo
First Posted Date
2011-12-02
Last Posted Date
2017-09-05
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
24
Registration Number
NCT01484587

Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil

Phase 4
Completed
Conditions
Alzheimer's Disease
Interventions
Drug: Galantamine
First Posted Date
2011-11-23
Last Posted Date
2014-03-26
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
102
Registration Number
NCT01478633

A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple Myeloma

Phase 1
Completed
Conditions
Multiple Myeloma
Interventions
Drug: JNS002
First Posted Date
2011-06-10
Last Posted Date
2013-07-04
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
3
Registration Number
NCT01371227

A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection

First Posted Date
2011-06-06
Last Posted Date
2014-05-05
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
79
Registration Number
NCT01366638

A Long-Term Study on Safety of JNS001 in Adults With Attention-Deficit Hyperactivity Disorder

Phase 3
Completed
Conditions
Attention-Deficit / Hyperactivity Disorder
Interventions
Drug: JNS001
First Posted Date
2011-05-23
Last Posted Date
2014-03-28
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
253
Registration Number
NCT01357993

An Efficacy and Safety Study for JNS001 in Adults With Attention-Deficit Hyperactivity Disorder

First Posted Date
2011-03-25
Last Posted Date
2013-09-06
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
284
Registration Number
NCT01323192

A Safety and Efficacy Study of Oral Tapentadol Extended-Release in Japanese Participants

Phase 3
Completed
Conditions
Neoplasms
Interventions
Drug: Tapentadol ER
Drug: Morphine SR
First Posted Date
2011-03-07
Last Posted Date
2013-03-13
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
100
Registration Number
NCT01309386

A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma

Phase 1
Terminated
Conditions
Multiple Myeloma
Interventions
Drug: Siltuximab
First Posted Date
2011-03-07
Last Posted Date
2014-05-19
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
9
Registration Number
NCT01309412

An Efficacy and Safety Study of Paliperidone Palmitate in Participants With Schizophrenia

Phase 3
Completed
Conditions
Schizophrenia
Interventions
Drug: Paliperidone palmitate
Drug: Placebo
First Posted Date
2011-02-18
Last Posted Date
2013-06-17
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
323
Registration Number
NCT01299389

A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients

First Posted Date
2011-02-09
Last Posted Date
2014-01-17
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
183
Registration Number
NCT01292239
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy